Fig. 6.
![Fig. 6. Comparison of the immunotherapy achieved against BCL1 with anti-Id IgG and BsAb. / Groups of 5 huCD64+ age-matched mice received the treatment schedule shown in Figure 3. However, mice were inoculated with 105 BCL1 tumor cells intraperitoneally on day 0 and were treated with twice-daily doses of (a) 0.1, (b) 1, (c) 10, or (d) 100 μg mAb or BsAb intraperitoneally on days 1 to 5 (either 1, 10, 100, or 1000 μg in total/mouse). Treatment was as indicated: PBS (●), anti-Id IgG (▵), or [huCD64 × Id] BsAb (○). Symbols on plots show antibody specificity. Survival was recorded daily, and similar results were obtained in at least 3 similar experiments.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/96/10/10.1182_blood.v96.10.3544/5/h82200347006.jpeg?Expires=1725294459&Signature=dEtjIBSMsPkEqpEc01pWWawshKuQHqQtgSQ5-26ovRHIXLWRZUjygXqGwHwz~dN5rgMM2HT8AyBrMXsm-wr5y9-laGJ8vNTYOLvs90~CwRhVfr3K1BLxCy5ZB-Sl2fLEIKRKTtbedosy0kpMAg26WRZ3gG-zdxYQWdsHmxqeG~gAIT68GXCUuDmcvlB8g9UT-29bJsBItrr3DDBYHn4kwCufA8CG6SSwHuXR9D0b6xy95jiCmDGbVdjOKsDstDqCt7xNttPL1OfcBzvVj32djjxhEjwSui2k0SPanWtCxIQMHholGHea6CF4GTtde8tEBzEiV1M9ijX1vbCjKE0buw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Comparison of the immunotherapy achieved against BCL1 with anti-Id IgG and BsAb.
Groups of 5 huCD64+ age-matched mice received the treatment schedule shown in Figure 3. However, mice were inoculated with 105 BCL1 tumor cells intraperitoneally on day 0 and were treated with twice-daily doses of (a) 0.1, (b) 1, (c) 10, or (d) 100 μg mAb or BsAb intraperitoneally on days 1 to 5 (either 1, 10, 100, or 1000 μg in total/mouse). Treatment was as indicated: PBS (●), anti-Id IgG (▵), or [huCD64 × Id] BsAb (○). Symbols on plots show antibody specificity. Survival was recorded daily, and similar results were obtained in at least 3 similar experiments.
